Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems

• Главные авторы: Pengcheng Zhang (Автор), He Tao (Автор), Liyang Yu (Автор), Lixiao Zhou (Автор), Chenggang Zhu (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Injectable implants with the ability to form in situ are one of the most promising carriers for the delivery of chemotherapeutic drugs to tumor sites. We have reported a novel injectable in situ-forming implant system composed of n-butyl-2-cyanoacrylate (NBCA), ethyl oleate, along with the sol-gel p...